These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 10669267)

  • 21. Thrombin inhibition with melagatran does not attenuate renal ischaemia-reperfusion injury in rats.
    Nitescu N; Grimberg E; Ricksten SE; Marcussen N; Guron G
    Nephrol Dial Transplant; 2007 Aug; 22(8):2149-55. PubMed ID: 17405786
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
    Boström SL; Dagnelid E; Hansson GF; Ulvinge JC
    Blood Coagul Fibrinolysis; 2004 Jan; 15(1):25-30. PubMed ID: 15166940
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
    Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
    Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
    Klement P; Carlsson S; Rak J; Liao P; Vlasin M; Stafford A; Johnston M; Weitz JI
    J Thromb Haemost; 2003 Mar; 1(3):587-94. PubMed ID: 12871470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
    Eriksson UG; Bredberg U; Gislén K; Johansson LC; Frison L; Ahnoff M; Gustafsson D
    Eur J Clin Pharmacol; 2003 May; 59(1):35-43. PubMed ID: 12743672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lipid peroxidation induced by an early inflammatory response in endotoxaemia.
    Basu S; Eriksson M
    Acta Anaesthesiol Scand; 2000 Jan; 44(1):17-23. PubMed ID: 10669266
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
    Koestenberger M; Gallistl S; Muntean W; Leschnik B; Fritsch P; Cvirn G
    Thromb Haemost; 2005 Jul; 94(1):69-74. PubMed ID: 16113786
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Melagatran for thromboprophylaxis after mechanical valve implantation: results in a heterotopic porcine model.
    Thompson JL; Hamner CE; Potter DD; Lewin M; Sundt TM; Schaff HV
    J Thorac Cardiovasc Surg; 2007 Aug; 134(2):359-65. PubMed ID: 17662773
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
    Wolzt M; Sarich TS; Eriksson UG
    Semin Vasc Med; 2005 Aug; 5(3):254-8. PubMed ID: 16123912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
    Evans HC; Perry CM; Faulds D
    Drugs; 2004; 64(6):649-78. PubMed ID: 15018597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Direct thrombin inhibitor prevents delayed graft function in a porcine model of renal transplantation.
    Giraud S; Thuillier R; Belliard A; Hebrard W; Nadeau C; Milin S; Goujon JM; Manguy E; Mauco G; Hauet T; Macchi L
    Transplantation; 2009 Jun; 87(11):1636-44. PubMed ID: 19502954
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
    Mattsson C; Menschiek-Lundin A; Wåhlander K; Lindahl TL
    Thromb Haemost; 2001 Aug; 86(2):611-5. PubMed ID: 11522011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition.
    Koestenberger M; Gallistl S; Cvirn G; Roschitz B; Rehak T; Leschnik B; Muntean W
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):131-7. PubMed ID: 15091000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Propofol (Diprivan-EDTA) counteracts oxidative injury and deterioration of the arterial oxygen tension during experimental septic shock.
    Basu S; Mutschler DK; Larsson AO; Kiiski R; Nordgren A; Eriksson MB
    Resuscitation; 2001 Sep; 50(3):341-8. PubMed ID: 11719164
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
    Gustafsson D; Nyström J; Carlsson S; Bredberg U; Eriksson U; Gyzander E; Elg M; Antonsson T; Hoffmann K; Ungell A; Sörensen H; Någård S; Abrahamsson A; Bylund R
    Thromb Res; 2001 Feb; 101(3):171-81. PubMed ID: 11228340
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
    Elg M; Börjesson I; Carlsson S
    Biopharm Drug Dispos; 2003 Sep; 24(6):251-7. PubMed ID: 12973822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
    Eriksson H; Eriksson UG; Frison L; Hansson PO; Held P; Holmström M; Hägg A; Jonsson T; Lapidus L; Leijd B; Stockelberg D; Säfwenberg U; Taghavi A; Thorsén M
    Thromb Haemost; 1999 Mar; 81(3):358-63. PubMed ID: 10102460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of low and high dose melagatran and other antithrombotic drugs on platelet aggregation.
    Soslau G; Ando A; Floyd L; Hong T; Mathew L; Yen Y
    J Thromb Thrombolysis; 2008 Apr; 25(2):198-203. PubMed ID: 17710375
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
    Mattsson C; Björkman JA; Abrahamsson T; Nerme V; Schatteman K; Leurs J; Scharpé S; Hendriks D
    Thromb Haemost; 2002 Apr; 87(4):557-62. PubMed ID: 12008935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of adenosine on cardiopulmonary functions and oxygen-derived variables during endotoxemia.
    Thiel M; Kreimeier U; Holzer K; Moritz S; Peter K; Messmer K
    Crit Care Med; 1998 Feb; 26(2):322-37. PubMed ID: 9468172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.